Nuo Therapeutics Inc  

(Public, OTCMKTS:NUOTQ)   Watch this stock  
Find more results for OTC:CMXI
May 9 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.29
Open     -
Vol / Avg. 0.00/75,611.00
Mkt cap 2.23M
P/E     -
Div/yield     -
EPS -0.06
Shares 125.68M
Beta 0.25
Inst. own 0%

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -637.52% -243.28%
Operating margin -1256.63% -301.35%
EBITD margin - -229.69%
Return on average assets -169.06% -36.85%
Return on average equity -430.66% -88.28%
Employees 46 -
CDP Score - -


207a Perry Pkwy Ste 1
United States - Map
+1-240-4992680 (Phone)
+1-240-4992690 (Fax)

Website links


Nuo Therapeutics, Inc., formerly Cytomedix, Inc., is a regenerative therapies company developing and marketing products within the United States and internationally through its strategic partners. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's commercial offerings are centered on its point of care platform technologies for the separation of blood and bone marrow to produce platelet based therapies or cell concentrates. It is promoting two distinct platelet rich plasma (PRP) technologies: the Aurix System for wound care, and the Angel concentrated Platelet Rich Plasma (cPRP) System for orthopedics and cardiovascular markets. The Company is focused on developing product candidates utilizing the Bright Cell technology platform, owned by its subsidiary, Aldagen, Inc.

Officers and directors

Joseph Del Guercio Acting Chairman of the Board
Age: 43
David Emerson Jorden CPA Chief Executive Officer, Chief Financial Officer, Director
Age: 52
Peter A. Clausen Ph.D. Chief Science Officer
Age: 49
Shaun C Martin Chief Restructuring Officer
Lawrence Atinsky Director
Lyle A. Hohnke Ph.D. Independent Director
Age: 72
Mark T. McLoughlin Independent Director
Age: 60
C. Eric Winzer Independent Director
Age: 58